Proven Efficacy in Clinical Trials Totalling 274 Patient-years of Treatment

Results

• Height velocity increased in the first year, on average, to 8 cm/year from a baseline of 2.8 cm/year, nearly tripling the rate of growth (P<0.0001)¹
• In years 2 through 6, height velocity was sustained at approximately 5 cm/year.¹
• Change in bone age was appropriate for chronological age¹

GROWTH RATE INCREASES WITH INCRELEX¹*

No patients dropped out of the trial due to adverse events:

• Data shown are from individuals treated continuously in 5 clinical studies: 4 open label and 1 double blind, placebo controlled
• Pre-treatment height velocity data were available for 58 subjects
• 71 children 2 to 10 years old with average height SD score of -6.7 due to Primary IGFD. Mean treatment time was 3.9 years with 274 total patient-years of treatment¹

*95% confidence intervals are shown

CUMULATIVE CHANGE IN HT-SDS WITH INCRELEX¹

Increlex improved height standard deviation scores¹

• Data shown are from individuals treated continuously in 5 clinical studies: 4 open label and 1 double blind, placebo controlled
• Year 1 height was available for 61 subjects
• Pre-treatment HT-SDS was -6.7 ± 1.8. By the end of the first year, the mean HT-SDS increased by 0.8 (P<0.0001), paired test, and had increased by 1.5 at year 8.

*95% confidence intervals are shown

Email the Increlex website to a friend       Print this page